MDB Capital Holdings, LLC Earnings Call Transcripts
Fiscal Year 2026
-
The strategy is shifting from scaling to monetizing portfolio assets and operating more leanly amid a weak micro-cap market. Planned spinouts, AI-enabled PatentVest expansion, and a potential Paulex Bio IPO next year are key catalysts.
-
Management is focused on monetizing four core assets, maintaining lean operations, and avoiding dilution. Key milestones include a potential Public Ventures deal, a PatentVest spinout, and upcoming value inflection points for eXoZymes and Paulex Bio.
-
The presentation outlined a strategy centered on building and launching companies with foundational IP, leveraging a full-stack platform and spinning out key subsidiaries. Despite a challenging microcap environment, the team maintains a strong IPO track record and is focused on scalable, high-upside opportunities.
Fiscal Year 2025
-
Management is optimistic about scaling company launches using AI, with four principal assets poised for significant value creation. Operating expenses are expected to decrease post-spinout of MDB Direct and PatentVest, while distribution and execution risks remain key challenges.
-
Management remains optimistic despite market headwinds, expecting a strong Q4 and multiple company launches next year. Significant equity positions in portfolio companies and new initiatives like the Patentvest spinout are poised to drive future value.
-
The conference highlighted a shift from microcap to 'public venture,' emphasizing curated, leadership-driven IPOs and a unique platform with in-house legal and brokerage services. With a strong IPO track record and renewed optimism for small-cap markets, the focus is on scaling launches and targeting high-growth sectors like metabolic health.
-
Revenue was minimal this quarter due to no financings, but PatentVest contributed as operations scale. Strategic focus is shifting to profitable, high-growth companies, with Buda Juice as a new IPO prospect and PatentVest set for a 2026 spin-off.
-
Curating public venture capital, the firm is leveraging a strong IPO track record and pivoting to bring more profitable, capital-light companies public amid challenging market conditions. Three new LOIs are in the pipeline, and the platform is scaling to broaden investor reach.
Fiscal Year 2024
-
eXoZymes was successfully IPO'd and deconsolidated, clarifying financials and resulting in a significant gain. The focus is on expanding the investor base and launching more curated public venture opportunities, with three to four new big ideas expected in 2025.
-
Transforming big ideas into public companies, the firm leverages a capital-light, hands-on model, recently highlighted by Invizyne's IPO. Despite tough micro-cap markets, a strong pipeline, robust cash position, and active community engagement position the company for future value creation.
-
A $15 million IPO is set to launch at $4 per share, featuring a unique long-term investor right (LTIR) that rewards investors who hold shares for two years if the stock does not double. The LTIR aims to provide downside protection and attract committed, long-term holders.